This article first appeared on GuruFocus .
-
Net Sales:Decreased by 14.6% to 166 million.
-
Organic Growth:Decreased by 6.6% due to an 8% currency headwind.
-
EBITDA:$40 million, representing 24%.
-
Gross Margin:68%.
-
Operating Expenses:51%, up from 41%, with a higher spend of 5 million.
-
Operating Cash Flow:$62 million.
-
Total Cash Flow:$42 million.
-
Cash and Cash Equivalents:$230 million on the balance sheet.
-
Americas Organic Growth:13%.
-
EMEA Growth:Decreased by 32%, with a 26% organic decline.
-
APAC Growth:10%, totaling $22 million.
-
Instrument Revenue:$86 million, down from $115 million in the comparable quarter.
-
Reagent Business Revenue:Almost 4 million, up from 1.4 million.
-
Software and Others:Decreased by 2%.
-
Warning! GuruFocus has detected 7 Warning Signs with FRA:2LU.
-
Is CLVSF fairly valued? Test your thesis with our free DCF calculator.
Release Date: April 24, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
CellaVision AB ( CLVSF ) reported strong momentum in the Americas with 13% organic growth, driven by the adoption of integrated large instruments in the hospital community.
-
The company launched the Celevations bone marrow aspirate application after receiving CE mark, with expectations for revenue contributions in the second half of 2026.
-
CellaVision AB ( CLVSF ) introduced a significant software upgrade, enhancing user interface and workflow features, which is expected to improve processing speed and efficiency.
-
The company is expanding its presence in the APAC region, with 10% growth and diversification beyond China into Southeast Asia.
-
CellaVision AB ( CLVSF ) maintains a strong cash position with $230 million in cash and cash equivalents, supporting ongoing investments and operations.
Negative Points
-
Net sales decreased by 14.6% due to lower sales in EMEA, primarily caused by inventory adjustments with a main distribution partner.
-
The company experienced a significant negative growth of 32% in EMEA, attributed to temporary inventory reductions and market uncertainties.
-
Operating expenses increased to 51% from 41%, reflecting higher spending and changes in capitalization of development expenditures.
-
R&D expenses were elevated at $30 million, with expectations for a decrease in future quarters as capitalization of early-stage projects begins.
-
The company faces challenges in the EMEA region due to public funding pressures and delayed tender activities, impacting sales growth.
Q & A Highlights
Q: Could you provide more details on the inventory situation in EMEA and its potential impact on the second quarter? A: Simon Ostergaard, CEO: The inventory buildup likely occurred throughout last year due to ERP implementations. We believe most of the excess inventory will be resolved this quarter, but some may spill over into the next quarter.
Q: Can you elaborate on the European public healthcare budget constraints and their impact on your business? A: Simon Ostergaard, CEO: There is pressure on healthcare budgets due to increased defense spending in some countries, causing delays in tender processes. This is particularly noticeable in countries like the UK.
Q: What initiatives are you taking to improve sales of small instruments in the Americas? A: Simon Ostergaard, CEO: We are focusing on integrated health networks (IHNs) where smaller labs are connected under larger labs. This involves training our partner Sysmex to promote the value of our DC-1 instrument in these networks.
Q: Regarding the bone marrow application, what are your expectations for its contribution to growth this year? A: Simon Ostergaard, CEO: We expect the bone marrow application to contribute to growth in the second half of the year, potentially adding 1-2% to company growth as we build the sales funnel.
Q: Are there any risks of inventory overhang in the Americas similar to EMEA? A: Simon Ostergaard, CEO: There are no significant inventory issues with large instruments in the U.S., but small instruments may still face some challenges due to previous uncertainties around tariffs.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
